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Background: Although some studies conducted outside of Japan have addressed the effectiveness of intravenous
immunoglobulins (IVIG) in treating infections, the dosing regimens and amounts used in Japan are very different
from those reported. Here, we investigate the effectiveness of single-dose administration of IVIG in sepsis patients
in Japan.
Methods: We analyzed 79 patients admitted to the intensive care unit (ICU) of a tertiary care institution due to
severe sepsis or septic shock. Patients were randomly divided into a group that was administered standard divided
doses of IVIG (5 g/day for 3 days, designated the S group) or a group that was administered a standard single dose
of IVIG (15 g/day for 1 day, H group); freeze-dried sulfonated human IVIG was used. The longitudinal assessment of
procalcitonin (PCT) levels, C-reactive protein (CRP) levels, white blood cell count, blood lactate levels, IL-6 levels,
Sequential Organ Failure Assessment (SOFA) score, and Systemic Inflammatory Response Syndrome (SIRS) was
conducted. We also assessed mechanical ventilation duration (days), ICU stay (days), 28-day survival rate, and 90-day
survival rate.
Results: The study showed no significant differences in PCT levels, CRP levels, 28-day survival rate, and 90-day
survival rate between the two groups. However, patients in the H group showed improvements in the various SIRS
diagnostic criteria, IL-6 levels, and blood lactate levels in the early stages after IVIG administration. In light of the
non-recommendation of IVIG therapy in the Surviving Sepsis Campaign Guidelines 2012, our findings of significant
early post-administration improvements are noteworthy. IVIG's anti-inflammatory effects may account for the early
reduction in IL-6 levels after treatment, and the accompanying improvements in microcirculation may improve
blood lactate levels and reduce SOFA scores. However, the low dosages of IVIG in Japan may limit the anti-cytokine
effects of this treatment. Further studies are needed to determine appropriate treatment regimens of single-dose
IVIG.
Conclusions: In this study, we investigated the effectiveness of single-dose IVIG treatment in patients with severe
sepsis or septic shock. Although there were no significant effects on patient prognoses, patients who were
administered single-dose IVIG showed significantly improved IL-6 levels, blood lactate levels, and disease severity
scores.
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Sepsis refers to a set of syndromes that occur as a result
of a systemic inflammatory response to an infection.
Without appropriate treatment, there is a high incidence
of supervening disseminated intravascular coagulation
(DIC) or multiple organ failure (MOF) [1], leading to ex-
tremely poor outcomes for patients.
In 2004, the Surviving Sepsis Campaign Guidelines
(SSCG), a set of comprehensive management guidelines
for the treatment of sepsis, were published [2]; the most
recent revision—SSCG 2012—was published in 2013 [3].
These guidelines contain details on initial resuscitation,
antimicrobial therapy, and infection source control.
Although the use of intravenous immunoglobulins
(IVIG) has been approved for the treatment of immune
diseases such as idiopathic thrombocytopenic purpura
and Kawasaki disease, its use in severe infections or
sepsis has yet to be approved by the US Food and Drug
Administration (FDA) and has also been discouraged in
SSCG 2012 as a treatment for adult sepsis patients.
However, IVIG has been shown to be effective in treating
severe infections [4,5], and several reviews have demon-
strated the efficacy of IVIG as a supplemental drug for
treating sepsis [6-9]. In the early stage of sepsis, low con-
centration of immunoglobulins is predicted because IgG
production in patients with primary infection needs 1–2
weeks, and lots of IgG are burned up for inhibiting bac-
teria and toxin in secondary infection. Therefore, it is
expected that IVIG administration for treatment of sepsis
is effective [10]. Furthermore, there are reports [11,12]
that a single dose of IVIG for Kawasaki disease and idio-
pathic thrombocytopenic purpura is more effective than
divided doses. In Japan, IVIG administration is approved
for severe infection, but the standard dosages and admin-
istration (5 g/day for 3 days) are far below the amount on
several reports set forth above. Therefore, we tested the
hypothesis that a single-dose IVIG treatment in patients
with severe sepsis and septic shock in Japan is more effect-
ive than divided doses.
Methods
This study was approved by an internal ethics committee
at its inception. In addition, the purpose of the study
was explained to candidate research subjects or their
legal representatives either verbally or in writing, and
written informed consent was obtained for each partici-
pant before their inclusion in the study.
Study sample
The study sample comprised patients who were admit-
ted to the intensive care unit (ICU) of a tertiary care
urban hospital between July 2009 and August 2012, and
fulfilled the diagnostic criteria for severe sepsis or septic
shock [13]. All study participants were immediately startedon early goal-directed therapy [14] after diagnosis of severe
sepsis or septic shock, using therapeutic strategies compli-
ant with SSCG 2008 [15]. Patients were excluded from
analysis if they fulfilled the following criteria: patients aged
17 years or younger, patients with existing allergies to IVIG
or antibiotics, patients with severe liver dysfunction or
kidney disease (except for organ dysfunctions that can be
caused by sepsis), patients with malignant neoplasms, pa-
tients in an immunodeficient state, patients who had acute
myocardial infarctions or heart failures within 6 weeks
prior to the index admission, patients (or their legal repre-
sentatives) who did not consent to participating in the
study, and patients deemed inappropriate for the study by
the principal investigating clinician.
Research subjects were randomly allocated into two
groups: a standard divided IVIG dose (5 g/day for 3 days)
group designated as the S group and a standard single
dose (15 g/day for 1 day) group designated as the H group.
These regimens were based on dosages and administra-
tion approved for severe infection in Japan.
In both groups, treatment using freeze-dried sulfonated
human IVIG was initialized within 24 h of diagnosing sep-
sis. Patient characteristics were evaluated using age; gen-
der; height; weight; Acute Physiology and Chronic Health
Evaluation (APACHE) II score; APACHE II score ex-
cluding Glasgow Coma Scale (GCS), APACHE(−GCS);
Sequential Organ Failure Assessment (SOFA) score; SOFA
score excluding GCS, SOFA(−GCS); disease severity clas-
sification; and underlying disease that led to sepsis.
The various values of the following diagnostic criteria
were longitudinally assessed throughout each patient's
hospitalization episode: procalcitonin (PCT) levels, C-reactive
protein (CRP) levels, white blood cell (WBC) count,
blood lactate levels, SOFA score, SOFA(−GCS) score, and
Systemic Inflammatory Response Syndrome (SIRS).
In addition, we also analyzed the following outcome
measures to evaluate patient prognosis: mechanical ven-
tilation duration (in days), ICU stay duration (in days),
28-day survival rate, and 90-day survival rate. With the
day of initial IVIG administration designated as day 1,
the longitudinal assessments of patient baseline and
clinical characteristics were conducted on days 1, 2,
3, 4, and 8 (Figure 1). Various parameters for day 1 were
assessed on ICU admission, and assessments for days 2
and 3 of the S group were conducted prior to IVIG ad-
ministration for that day. Also, plasma IL-6 was extracted
and cryopreserved at the various time points, and IL-6
plasma concentration was measured using chemilumines-
cent enzyme immunoassay (Human IL-6 CLEIA, Fujirebio
Corp., Tokyo, Japan).
Many of the research subjects in this study had under-
gone mechanical ventilation or had been administered sed-
atives, but assessments of the central nervous system in
such patients have been reported to be heavily dependent
Figure 1 Schedule of IVIG administration and clinical data collection time points. White arrows indicate IVIG administration, whereas black
arrows indicate data collection. IVIG, intravenous immunoglobulin.






Age (years) 66.7 ± 2.0 67.7 ± 2.2 0.744
Gender (male/female) 21/21 25/12 0.057
Body height (cm) 159.9 ± 1.4 161.4 ± 1.6 0.465
Body weight (kg) 54.6 ± 2.0 53.5 ± 2.0 0.699
APACHE II score 25.5 (13–39) 27 (8–43) 0.115
APACHE II(−GCS) 17 (8–29) 17 (8–32) 0.936
SOFA score 11 (3–15) 10 (4–17) 0.462





Generalized peritonitis 15 (35.7%) 13 (35.1%)
Pneumonia 4 (9.5%) 6 (16.2%)
Urinary tract 6 (14.3%) 2 (5.4%)
Bacteremia 4 (9.5%) 3 (8.1%)
Cellulitis 2 (4.8%) 2 (5.4%)
Biliary tract 2 (4.8%) 1 (2.7%)
Others 5 (11.9%) 6 (16.2%)
Unknown 4 (9.5%) 4 (10.8%)
aPatients in the S group were administered a standard IVIG dose of 5 g/day for
3 days; patients in the H group were administered a single high dose of 15
g/day for 1 day. Continuous variables: mean ± SEM; ordinal variables: median
(interquartile); nominal variables: percentage. APACHE II, Acute Physiology and
Chronic Health Evaluation II; APACHE II(−GCS), APACHE II without Glasgow
Coma Scale; SOFA, Sequential Organ Failure Assessment; SOFA(−GCS), SOFA
without Glasgow Coma Scale.
Hamano et al. Journal of Intensive Care 2013, 1:4 Page 3 of 7
http://www.jintensivecare.com/content/1/1/4on the individual assessor [16]. Therefore, we have in-
cluded APACHE II scores and SOFA scores that omit
GCS assessment, which measures the level of patient con-
sciousness. In addition, APACHE II scores should be eval-
uated by using the worst value in the first 24 h, under
normal circumstances. However, we evaluated APACHE II
scores by the worst value from ICU admission to initial
IVIG administration, as IVIG should be administered as
soon as possible for treating sepsis.
Statistical analysis
For assessments of patient characteristics between the
two groups, we used the unpaired t test, Mann-Whitney
U test, chi-square test for independence, and Fisher's
exact test as appropriate for the data type for each vari-
able. Transitions in clinical data were assessed using un-
paired t tests. Changes in the various time points within
each of the two groups were also analyzed using one-way
analysis of variance (ANOVA), followed by a multiple
comparison using Scheffe's method. Continuous variables
were presented as mean values ± standard error of the
mean (SEM), whereas ordinal variables were presented as
median values (interquartile range (IQR)).
Patient prognoses were measured using Kaplan-Meier
survival curves and the log-rank test. Statistical signifi-
cance was set at P < 0.05. All statistical analyses were




Patient characteristics are presented in Table 1. The 79
research subjects in the study had a mean age of 67.2 ±
1.5 years, and the 28-day and 90-day survival rates were
86.1% and 78.5%, respectively. The APACHE II score was
27 (IQR 8–42), and the SOFA score was 10 (IQR 3–17).
The most frequent source of infection for both groups
was generalized peritonitis. The H group had a slightly
higher proportion of men, whereas the S group had more
patients presenting with urinary tract infections. However,there were no differences between the two groups with re-
spect to the proportion of patients with severe sepsis or
septic shock, and no statistically significant differences in
patient characteristics were observed.
Temporal transitions in clinical data
There were no significant differences in temporal transi-
tions in PCT values observed between the two groups
(Figure 2a). Similar results were observed for CRP values
Figure 2 Time course results of laboratory data. (a) PCT levels, (b) CRP levels, and (c) WBC count. Solid lines indicate the H group, and dashed
lines indicate the S group.
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significant difference in blood lactate levels on day 2
between both groups (P = 0.02), as shown in Figure 3.
The H group was found to have significantly lower
SOFA and SOFA(−GCS) scores in the early stages after
IVIG administration (SOFA score for day 3: P = 0.04;
SOFA(−GCS) score for day 3: P = 0.04), with differences
continuing for the first week (Figure 4a,b). With regard to
the various diagnostic criteria for SIRS, we also observed
significantly lower scores (day 2: P < 0.01) in the H group
in the early stages after IVIG administration (Figure 4c).
In addition, the results revealed a general tendency for
temporal reductions in IL-6 levels in the H group across
the time points, although this tendency was not found
to have overall statistical significance. However, Figure 5
shows a statistically significant reduction (P < 0.01) in
IL-6 levels in the H group between day 1 and day 2,
whereas this was not observed in the S group. For the
difference between day 2 and day 3, both groups showed
a significant reduction in IL-6 levels.Figure 3 Time course results of blood lactate levels. *P < 0.05
when compared with the S group. Solid line indicates the H group,
and dashed line indicates the S group.Clinical course
There were no significant differences in mechanical venti-
lation duration between the two groups or in the propor-
tions of patients who had undergone tracheal intubation.
Additionally, there were also no significant differences in
ICU stay duration.
Patient prognosis
Kaplan-Meier survival curves and the log-rank test dem-
onstrated that the H group tended to have higher, albeit
non-significant, 28-day survival rates and 90-day survival
rates when compared with the S group (not shown in
the figure).
Discussion
Despite dramatic progress in treatment modalities, mor-
tality rates for patients with serious sepsis remain high
[17,18], and a meta-analysis conducted by Friedman et al.
[19] has shown the mortality rate associated with septic
shock patients to be 49.7%. Factors such as the over-
all increases in patient age, advances in drug therap-
ies, increasingly complex surgical procedures, and the
emergence of multiple drug-resistant bacteria are thought
to contribute to the continued increase in the number of
patients with sepsis [20]. There is, therefore, an urgent
need to further advance treatment modalities and adjunct-
ive therapies.
In SSCG 2008 [15], the administration of IVIG was
recommended in children due to a study [21] that dem-
onstrated reduced mortality as a result of this treatment.
However, this recommendation did not extend to in-
clude adult patients. Subsequently, the recommendation
for IVIG administration was rescinded in the SSCG
2012 [3] due to studies such as the large-scale multi-
institutional collaborative SBITS study involving 624
adult patients [22] and an investigation of 3,493 children
[23]. In contrast, while the Japanese Guidelines for the
Management of Sepsis [24] have not acknowledged the
ameliorative effects of IVIG treatment on mortality
Figure 4 Time course results of (a) SOFA score, (b) SOFA(−GCS), and (c) SIRS criteria. *P < 0.05, **P < 0.01 when compared with the S
group. Solid lines indicate the H group, and dashed lines indicate the S group. SOFA, Sequential Organ Failure Assessment; GCS, Glasgow Coma
Scale; SIRS, Systemic Inflammatory Response Syndrome.
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ered in the early stages of therapy as a means to reduce
mechanical ventilation duration and improve survival
rates in the ICU [22].
The regimen and dosage of IVIG in Japan are substan-
tially lower than in many other countries. A study
conducted in Japan in 2000 [25] analyzed the effects
when patients with infections who showed no improve-
ment in symptoms after 3 days of antibiotic therapy were
administered IVIG (5 g/day for 3 days). When compared
with similar patients who were not administered IVIG, the
IVIG group showed significant improvements in disease
symptoms. Although the negative conversion rate of the
causative organism and the CRP rate of change were not
significantly different between the two groups, a compos-
ite score comprised of fever and other symptoms was de-
veloped to measure the effectiveness of the therapy, which
showed that the IVIG group had significantly higherFigure 5 Time course of IL-6 levels. *P < 0.01 compared with day
1 (H group only); †P < 0.01 compared with day 2 (both groups),
using one-way ANOVA, followed by a multiple comparison using
Scheffe's method. Solid line indicates the H group, and dashed line
indicates the S group. IL-6, Interleukin-6.effectiveness. However, the definition for severe sepsis was
unclear, and the outcome measures used (reductions in
fever and improvements in symptoms) were relatively am-
biguous. Therefore, the utilization standards, regimen, and
dosages reported in this study may be inconclusive.
Accordingly, we have conducted an investigation of
the effectiveness of single-dose IVIG in patients with se-
vere sepsis or septic shock. In this randomized con-
trolled study, we did not observe significant differences
between the two groups in CRP levels (a standard infec-
tion marker), PCT levels (which are thought to reflect the
severity of sepsis) [26,27], ICU stay duration, and patient
prognoses. However, when compared with the standard
divided doses IVIG group, the standard single-dose IVIG
group was shown to have better results in the early post-
administration stages for factors such as IL-6 levels, blood
lactate levels, and SOFA score.
The mechanism of action for IVIG against infections
has been reported to include the stimulation of Fc
receptor-mediated antibiotic-dependent cellular cytotox-
icity, neutralization of toxins and viruses, suppression of
cytokine activity, promotion of complement-mediated
bacteriolysis, and opsonization of targets to promote
phagocytosis [28]. As some aspects of the mechanism
still remain unclear, it would not be possible to conclu-
sively explain the findings of this study. However, the
fact [29] that IVIG formulations include anti-IL-6 anti-
bodies may account for the early reduction in IL-6 levels
after treatment, and the accompanying improvements in
microcirculation may ostensibly improve blood lactate
levels and reduce the SOFA score. A multi-institutional
study has shown that improvements to blood lactate levels
are associated with reductions in mortality risk [30], and
these findings resulted in the reestablishment of the
normalization of blood lactate levels at a recommended
measure in SSCG 2012 [3]. From this perspective, the
single-dose administration of IVIG could therefore also be
thought of as being an effective treatment. In this study,
we did not observe any adverse events occurring as a
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toms or thrombocytopenia.
There were several limitations in this study. First,
there may be a large degree of variation in the time to
treatment among the research subjects. Next, the dosage
of IVIG was not based on subject body weight but was
standardized for all subjects. Also, we did not account
for the anti-cytokine effects from other treatments such
as blood purification therapy, steroids, sivelestat, and re-
combinant thrombomodulin. Additionally, there is a
possibility that the pathology of sepsis differs according
to the underlying illnesses. Finally, the levels of IgG in
the blood were not assessed prior to administering IVIG,
and there may therefore be a large degree of variation in
these levels among the subjects.
A minimum of 2.0 g/kg body weight of immunoglobu-
lins has been reported to be necessary in order to suffi-
ciently neutralize the rise of IL-6 levels due to sepsis
[31], which would be difficult to achieve in Japan given
the reduced anti-cytokine effects from the lower im-
munoglobulin dosages. More studies are needed to fur-
ther understand the costs, risk of infection, mechanism
of utility, appropriate dosages, and modes of administra-
tion of single-dose IVIG treatment.
Conclusions
In this study, we shed light on the effectiveness of
single-dose IVIG treatment in patients with severe sepsis
or septic shock in Japan. Although the study did not show
any significant effects on patient prognoses, subjects who
were administered a standard single dose of IVIG showed
significantly improved early-stage IL-6 levels, blood lactate
levels, and disease severity scores when compared with
patients administered with standard divided doses.Competing interests
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